NCT04774419View on ClinicalTrials.gov

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 2, 2021

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Endometrial Cancer
Interventions
RADIATION

Intensity modulated radiation therapy (IMRT)

To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.

DRUG

Dostarlimab

IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.

RADIATION

Hypofractionated IMRT

Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11570

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Commack (All Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
collaborator

Tesaro, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER